Table 14.1/5 Demographic and Baseline Characteristics Randomized Subjects

		Placebo n=32	CMP-135 n=33	All Patients n=65
Age (yr)	Mean (SD)	59.0 (9.0)	54.8 (10.1)	56.9 (9.7)
	Median	57.5	56.0	56.0
	N	32	33	65
	Range	38 - 80	33 - 71	33 - 80
Age Group (yr)	18 - 40	1 (3.1%)	3 (9.1%)	4 (6.2%)
	41 - 64	22 (68.8%)	23 (69.7%)	45 (69.2%)
	>= 65	9 (28.1%)	7 (21.2%)	16 (24.6%)
	n	32	33	65
Current remission Status	2nd	26 (81.3%)	26 (78.8%)	52 (80.0%)
	3rd	6 (18.8%)	7 (21.2%)	13 (20.0%)
	n	32	33	65
ECOG Score	0	25 (78.1%)	24 (72.7%)	49 (75.4%)
	1	7 (21.9%)	9 (27.3%)	16 (24.6%)
	n	32	33	65
Ethnicity	Hispanic Or Latino	4 (12.5%)	2 (6.1%)	6 (9.2%)
	N	32	33	65
	Not Available	0 (0%)	0 (0%)	0 (0.0%)
	Not Hispanic Or Latino	28 (87.5%)	31 (93.9%)	59 (90.8%)
Race	American Indian Or Alaska Native		1 (3.0%)	1 (1.5%)
	Asian	1 (3.1%)	1 (3.0%)	2 (3.1%)
	Black Or African American	1 (3.1%)		1 (1.5%)
	Multiple		1 (3.0%)	1 (1.5%)
	N	32	33	65
	Not Available	0 (0.0%)	0 (0.0%)	0 (0.0%)
	White	30 (93.8%)	30 (90.9%)	60 (92.3%)
Sex	Female	32 (100.0%)	33 (100.0%)	65 (100.0%)
	n	32	33	65
Weeks from the last therapy	Mean (SD)	7.6 (3.2)	7.2 (3.1)	7.4 (3.1)
	Median	6.7	6.0	6.3
	N	32	33	65
	Range	4 - 14	3 - 14	3 - 14
Weight (kg) at (timepoint)	Mean (SD)	70.7 (13.1)	70.0 (8.9)	70.4 (11.1)
	Median	71.4	69.5	70.0
	N	32	33	65
	Range	47 - 94	54 - 90	47 - 94